VerAvanti seeks to become the world's foremost provider of cutting-edge, single use intravascular endoscopic technologies.
VerAvanti has raised $5.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
VerAvanti is headquartered in Bothell, United States.
VerAvanti seeks to become the world's foremost provider of cutting-edge, single use intravascular endoscopic technologies.
VerAvanti is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VerAvanti — Funding & Investors." VCBacked, October 20, 2025, https://www.vcbacked.co/company/veravanti. Accessed July 31, 2026.
VCBacked. (2025). VerAvanti — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/veravanti
{{cite web |title=VerAvanti — Funding & Investors |url=https://www.vcbacked.co/company/veravanti |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated